Table 2.
Pretreatment clinicoradiological characteristics (29 patients)
| Characteristics | Number of events (%) | |
|---|---|---|
| Vessel encasement | Vessel encasement >180° in 17 patients (58.6%) | |
| Superior mesenteric vein | 17 (36) | 10 (56) |
| Superior mesenteric artery | 13 (28) | 7 (39) |
| Portal vein | 6 (13) | — |
| Others | 11 (22) | 1 (6) |
| Total number of events | 47 | 18 |
| Neoadjuvant chemotherapy | ||
| Induction (gemcitabine) | 23 (80) | |
| Concomitant | ||
| 5-FU | 8 (28) | |
| Gemcitabine | 19 (65) | |
| 5 FU + Gemcitabine | 2 (7) | |
| Neoadjuvant radiation therapy | ||
| Modality | ||
| Three-dimensional | 17 (59) | |
| IMRT α | 12 (42) | |
| Total dose (Gy) | ||
| 45–50.4 | 16 (55) | |
| 54–60 | 11 (38) | |
| Non- specified | 2 (7) | |
| Total duration (days)b | 38 (37–41) | |
| Time from diagnosis to resection (months)a | 8 (6–9.3) | |
| Time from the end of radiation to resection (months)a | 2.7 (1.9–4.1) | |
| Pathological treatment effect (%)a | 80 (50–95) | |
a
Median (interquartile).
IMRT, intensity-modulated radiation therapy.